Is Charles River Laboratories (CRL) overvalued or fairly valued?

MarketChacha shows Charles River Laboratories's valuation in context — a forward P/E of about 17.9, a price-to-book of about 3.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Charles River Laboratories (CRL)?

Charles River Laboratories last traded at $221.31 (+0.9% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Charles River Laboratories

CRL · NYSE · Healthcare · United States

$221.31+0.9%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 5:32 PM

Snapshot

TickerCRL

ExchangeNYSE

SectorHealthcare

IndustryDiagnostics & Research

CountryUnited States

Employees18,300

HeadquartersWilmington, United States

Market cap$10.7B

P/B3.6

Volume211.95K

Websitewww.criver.com

Filings tracked0

About Charles River Laboratories

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.6%
Institutions99.4%
Public & other0.0%

789 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.8.01%
FMR, LLC7.18%
Vanguard Capital Management LLC6.65%
Invesco Ltd.4.98%
Vanguard Portfolio Management LLC4.76%
Harris Associates L.P.4.47%
Allspring Global Investments Holdings, LLC4.14%
State Street Corporation3.89%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $939.2M · EPS 3.05

Est. earnings growth +25.5%

Next fiscal year

Rev $3.9B · EPS 12.33

Est. earnings growth +11.0%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$144.2652-wk range$237.86

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about CRL

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.